Recent Articles

In January, Shanghai Base Biotech, a base editing company, completed an A1 financing that brought in tens of millions of dollars, according to a release. BaseBio develops base editing tools and off-the-shelf Super-NK cell therapies. The financing will be used to advance the company's candidates in its base editing therapeutic pipeline, including eight general-purpose off-the-shelf Super-NK products and in vivo editing therapies. The A1 round was led by Hong Kong's Great Eagle VC, BV Baidu Ventures, Xinxi Capital, Guangda Huitong, UK SPARK VC and other investors. Previously, BaseBio raised $14 million in Angel funding. More details....

Share this with colleagues:  

Shanghai Everest Medicines announced Xerava® (eravacycline) was approved in China to treat complicated intra-abdominal infections in adult patients. Xerava, which will be Everest’s first commercialized drug, is a novel parenteral broad-spectrum, fluorocycline antibiotic of the tetracycline class. It has shown broad in vitro activity against Gram-negative and Gram-positive pathogens with multidrug resistance. In 2018, Everest in-licensed Greater China rights for Xerava from Boston’s Tetraphase Pharma in a $43 million agreement. Xerava is already approved in the US, EU and other parts of the world. More details....

Stock Symbol: (HK 1952)

Share this with colleagues:  

Shanghai Mabwell has started a Phase I trial of 9MW301, the company’s iron homeostasis regulating macromolecular drug. The candidate is a mAb with an innovative target that Maxwell developed at its San Diego Innovation and R&D Center. In China, the mAb is a Category 1 Therapeutic Biological Product. 9MW3011 has been approved to begin trials in China and the US for two rare disease indications: β-thalassemia and polycythemia vera. In January 2023, Mabwell out-licensed global rights (ex-China) for the drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. More details....

Stock Symbol: (SHA: 688062)

Share this with colleagues:  

Nanjing Simcere Pharma will test its potential first-in-class anti-tumor necrosis factor receptor 2 (TNFR2) mAb with MSD's (Merck) anti-PD-1 therapy, Keytruda® (pembrolizumab). The trial, which will enroll patients with advanced solid tumors and cutaneous T-cell lymphoma (CTCL), will evaluate the safety and efficacy of SIM0235 as a monotherapy or in combination with Keytruda. A Simcere subsidiary, Simcere Zaiming, will conduct the trial and retain worldwide commercial rights to SIM0235. Formed earlier this year, Simcere Zaiming focuses on Simcere’s innovative cancer therapeutics. More details....

Stock Symbol: (HK: 2096)

Share this with colleagues:  

Shanghai Everest Medicines reported its in-licensed kidney drug, Nefecon, met its Phase III endpoints in patients with primary IgA nephropathy (IgAN). In 2019, Everest acquired China rights to Nefecon from Sweden’s Calliditas Therapeutics in an agreement worth up to $121 million. Calliditas conducted the global Phase III trial, which enrolled 364 patients randomized 1:1 for Nefecon and placebo. Everest said the trial showed Nefecon is a disease modifying first-in-disease treatment for IgAN patients. The trial included a China arm that is expected to release final data in Q3 of 2023. More details....

Stock Symbol: (HK:1952)

Share this with colleagues: